Utility of serological markers in inflammatory bowel diseases: Gadget or magic?

Table 1 Prevalence of different serologic markers in IBD and their association with disease phenotype

	Crohn’s disease(%)	Ulcerative colitis(%)	Healthy subjects(%)	Clinical significance
Atypical P-ANCA	2-28	45-82	1-7	Assists in differentiation between CD and UC: Atypical P-ANCA+/ASCA-: UC Atypical P-ANCA-/ASCA+: CD CD: ASCA+: ileal involvement, complicated disease course, early need for surgery
ASCA	41-76	5-15	5	Atypical P-ANCA+: left sided colitis, good therapeutical response, uncomplicated disease course UC: Atypical P-ANCA+: severe left sided colitis, refractory to medical therapy, early need for surgery
Anti-OmpC (IgA)	24-55	5-11	5	Identify ASCA- CD patients Penetrating disease Faster disease progression Early need for surgery
Anti-I2 (IgA)	54	10	4	Inflammatory enteritis (19%) Stricturing form Early need for surgery
Anti-CBir1 (IgG)	50	6	8	Flagellin (CBir1) induce colitis in animal models of IBD Leads to a pathological immune response in IBD patients Differentiation between atypical P-ANCA+ CD and UC Small bowel involvement Penetrating and stenosing form
Antiglycan antibodies (ALCA ACCA)	36	< 10	0	44% in ASCA- patients ALCA-penetrating; ACCA-stenosing form (small differences)
PAB (IIF)	27-39	2-6	0-2	High specificity, low sensitivity Significance? Distinct CD subgroup?